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ABSTRACT Streptococcus pneumoniae (pneumococcus) is a Gram-positive bacterium that causes serious invasive diseases, such
as pneumonia, bacteremia, andmeningitis, with highmorbidity andmortality throughout the world. Before causing invasive
disease, S. pneumoniae encounters cellular barriers, which are often composed of endothelial cells, like the alveolar-capillary
barrier and the blood-brain barrier. S. pneumoniae adheres to endothelial cells and may invade them, which requires an efficient
host response to the intracellular bacteria. The precise intracellular fate of S. pneumoniae during infection still remains a subject
of debate. The proteasome-ubiquitin system is largely responsible for the degradation of misfolded, damaged, or no-longer-
useful proteins. Recently, the role of the proteasome-ubiquitin system in the clearing of invading bacteria and viruses has been
more closely studied. In this study, we show that inhibition of the proteasome-ubiquitin system leads to a marked increase in
S. pneumoniae survival inside host cells. Immunofluorescence analysis showed that intracellular pneumococci colocalized with
proteasome and ubiquitin in human endothelial cells in vitro. Confocal imaging analysis demonstrated that in the brains of mice
intravenously infected with S. pneumoniae, the bacteria were inside endothelial cells, where they colocalized with proteasome
and ubiquitin signals. In conclusion, our data indicate that a fully functional proteasome-ubiquitin system in endothelial cells is
crucial for efficient killing of intracellular S. pneumoniae.
IMPORTANCE Bacterial meningitis is a serious invasive disease with high morbidity and mortality. How bacteria traverse the
blood-brain barrier in vivo and what mechanisms are employed by the host to prevent invasion are still unclear. Our data show
that inhibition of the proteasome-ubiquitin system in vitro leads to a significant increase in S. pneumoniae survival inside brain
endothelial cells. Confocal imaging analysis of brain tissue frommice intravenously infected with pneumococci demonstrated
that the bacteria are inside brain microvascular endothelial cells, where they associate with the proteasome and ubiquitin. This
is, as far as we know, the first report that demonstrates that Streptococcus pneumoniae invades endothelial cells of the blood-
brain barrier in vivo. The host requires the proteasome-ubiquitin system for an efficient decimation of intracellular S. pneu-
moniae.
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Streptococcus pneumoniae (pneumococcus) is a Gram-positivehuman pathogen that causes life-threatening invasive diseases
such as pneumonia, bacteremia, and meningitis with high mor-
bidity and mortality throughout the world. Cellular barriers en-
countered by S. pneumoniae before causing invasive disease are
often composed of endothelial cells. For instance, during pneu-
monia, the bacteria interact with endothelial cells in the alveolar-
capillary barrier before translocating from the lungs into the
bloodstream and causing bacteremia. S. pneumoniae also interacts
with the endothelium of the blood-brain barrier before invading
the central nervous system (CNS), leading to meningitis (1). Once
attached, in vitro S. pneumoniae organisms can invade endothelial
cells, where the majority of them are degraded in the lysosomes
(2–4). However, a minor subset of internalized S. pneumoniae
cells is most likely recycled out of the cell again, as exemplified by
the association with Rab markers (3, 4). Yet another subset of the
internalized S. pneumoniae cells is not killed or recycled but trans-
located from the apical side, through the cell, to the basolateral
side through a process called transcytosis (3–6), causing meningi-
tis. A similar degradation by the lysosome has been shown for
other bacteria, for instance Staphylococcus aureus and Legionella
pneumophila (7, 8).
To shed further light on the process determining S. pneu-
moniae degradation, we studied the possible involvement of the
proteasome-ubiquitin system in the killing of internalized
S. pneumoniae. The proteasome-ubiquitin system is largely re-
sponsible for the degradation of misfolded, damaged, or no-
longer-useful proteins. In order for a protein to be degraded, it
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needs to be tagged by the small (76-amino-acid) ubiquitin pro-
tein, which is covalently bound to the substrate via lysine residues
by the action of the E3-ubiquitin ligase. Prior to binding to the
substrate, the ubiquitin molecule needs to be activated in an
energy-dependent manner by the activating E1 enzyme, followed
by transfer of the ubiquitin from the activating E1 enzyme to the
conjugating E2 enzyme. The E2-ubiquitin complex is then docked
with the E3-ubiquitin ligase. This complex recognizes the protein,
which is to be degraded, and transfers the ubiquitin to the sub-
strate (9–12). In general, it seems that mono-ubiquitination (one
ubiquitin molecule bound to the substrate) functions mainly in
signaling, for example for the regulation of endocytosis, endo-
somal sorting, and trafficking (13, 14). In contrast, poly-
ubiquitination (many ubiquitin molecules bound to a substrate
either as monomers or in chains) leads to degradation of the sub-
strate in the proteasome or performs other regulatory functions,
including trafficking, kinase activation, and DNA repair (15–17).
In recent years, the role of the proteasome-ubiquitin system in the
innate immune system has come under close scrutiny (9), espe-
cially so with regard to its role in the clearing of invading bacteria
(18) and viruses (10). Here we investigated the role of the
proteasome-ubiquitin system in the intracellular fate of S. pneu-
moniae and show that, in vivo, the bacteria invade brain endothe-
lial cells, which need a fully functional proteasome-ubiquitin sys-
tem for efficient killing of intracellular S. pneumoniae.
RESULTS
A fully functional proteasome-ubiquitin system is required for
efficient intracellular killing of S. pneumoniae.To determine the
role of the proteasome-ubiquitin system in the killing of intracel-
lular S. pneumoniae, we used chemical inhibitors to block discrete
parts of the proteasome-ubiquitin system in endothelial cells in-
fected with pneumococci. To avoid any effect on the adhesion and
uptake mechanisms, all inhibitors were added after S. pneumoniae
had invaded and external S. pneumoniae cells had been either
washed away or killed with antibiotics, as described in Materials
and Methods. This approach, as opposed to adding inhibitors
from the start or even pretreating the endothelial cell cultures with
the inhibitors, yields less pronounced but more defined, relevant,
and reliable effects. Adding the inhibitors after the bacteria have
invaded the cells circumvents several problems. The cells are not
exposed to the chemicals for a long time and are not impaired in
their normal function, and thus decreases in viability are unlikely
to be a problem. Also with this approach, we are certain that the
effects that we observe are due to differences in intracellular sur-
vival and not invasion. It is important to note that even with the
short incubation time, we observed the effects described below.
We used the chemicals carbobenzoxy-L-leucyl-L-leucyl-L-leucinal
(MG132) (19, 20) and tetraethylthiuram disulfide (TET) (21–23)
for proteasome inhibition. The MG132 and TET treatments re-
sulted, respectively, in 79% and 253% increases in intracellular
S. pneumoniae survival compared to the survival of the organism
in the control experiment without inhibitor (Fig. 1A and see
Fig. S1 and S2 in the supplemental material). This strongly indi-
cated that a fully functional proteasome is required for efficient
killing of intracellular pneumococci. To further dissect the influ-
ence of the proteasome-ubiquitin system on S. pneumoniae sur-
vival inside the endothelial host cell, we inhibited the first step of
the ubiquitination process. The inhibitor UBEI-41 (also known as
PYR-41) (20) specifically inhibits the activating E1 enzyme, nec-
essary for the initial activation of the ubiquitin molecule, the first
step in a process ultimately resulting in the ubiquitination of tar-
get proteins (24). Inhibition of the ubiquitin-activating enzyme
with UBEI-41 resulted in a 142% increase in intracellular S. pneu-
moniae survival (Fig. 1B and S3).
The capsule of S. pneumoniae does not inhibit the
proteasome-mediated killing process. The capsule is one of
S. pneumoniae’s main virulence factors (25). However, it also im-
pedes adhesion and invasion into host cells, and it has been shown
that S. pneumoniae in close interaction with host cells loses its
capsule in the mouse nasopharynx (26). This is why we, like others
in the field (3, 4, 26), used unencapsulated bacteria to study the
S. pneumoniae-host cell interactions, especially so since this
greatly increases the adhesion and invasion frequency. However,
to exclude the possibility that encapsulated strains interact differ-
ently with the host cell and are trafficked through different cellular
pathways, we investigated the effect of proteasome inhibition with
an encapsulated strain. Proteasome inhibition also resulted in a
substantial (118%) increase in the intracellular survival of the en-
capsulated S. pneumoniae cells (Fig. 2). Thus, the involvement of
the proteasome system in the intracellular killing of S. pneumoniae
is independent of the presence of the capsule, and the bulk of
invading encapsulated S. pneumoniae cells also enter a cellular
trafficking pathway, which ultimately ends in their degradation.
Intracellular S. pneumoniae colocalizes with proteasome
and ubiquitin in vitro. Immunofluorescent analysis was used to
ascertain whether intracellular pneumococci colocalized with
proteasome and or ubiquitin. First we investigated whether a
combined treatment of antibiotics and lysozyme would be suffi-
cient for the removal of most extracellular bacteria, which inter-
fere with the specific study of intracellular bacteria. A combina-
FIG 1 A fully functional proteasome-ubiquitin system in endothelial cells is
crucial for efficient clearance of intracellular S. pneumoniae. (A) Relative sur-
vival of internalized S. pneumoniae cells during proteasomal inhibition with
MG132 or TET. The control is set at 100%, and the experimental conditions
are related to this percentage. Each circle represents the relative intracellular
survival in an individual experiment, and horizontal lines indicate the averages
of results from all experiments (n  6 and 3, respectively). P values  0.174
and0.05, respectively. Relative intracellular survival is defined as intracellu-
lar survival divided by the amount of the initial invasion. (B) Relative survival
of internalized S. pneumoniae during inhibition of the activating E1 enzyme
with the inhibitor UBEI-41. The control is set as 100%, and the experimental
conditions are related to this percentage. Each circle is the relative intracellular
survival in an individual experiment, and horizontal lines indicate the averages
of results from all experiments (n 6). P value 0.05. Relative intracellular
survival is defined as intracellular survival divided by the amount of the initial
invasion.
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tion of lysozyme and antibiotics was sufficient to lyse 99% of
bacteria grown in broth (Fig. S1). Comparing the amount of ex-
tracellular bacteria after treatment with a combination of ly-
sozyme and antibiotic with that after antibiotic treatment alone
using the Triton X-100 permeabilization method previously de-
scribed by Pracht et al. (27) (Fig. S2) clearly showed a drastic
reduction in numbers of extracellular bacteria when lysozyme was
added. At the same time, there was no apparent change in the
amount of intracellular bacteria. Immunofluorescence analysis
using this method showed that the intracellular pneumococci co-
localized with proteasome (Fig. 3A). Moreover, a ubiquitin signal
was detected on the bacteria in both human brain-derived micro-
vascular endothelial cells (HBMEC) and human umbilical vein-
derived endothelial cells (HUVEC) (Fig. 3B).
Intracellular S. pneumoniae cells are detected in mouse
brain tissue and also colocalize with ubiquitin and proteasome.
To validate our in vitro findings, confocal microscopy analysis was
performed on brain tissue from mice intravenously challenged
with pneumococci. Mice were and sacrificed 1 and 14 h after in-
fection, which represent the early and late stages of bacteremia
preceding the development of meningitis (1). We focused on the
subarachnoid space, as it was previously shown to be the anatom-
ical site of the blood-brain barrier where most S. pneumoniae bac-
teria were found (1). Remarkably, the confocal imaging analysis,
in particular, the XZ and YZ orthogonal views, clearly showed
S. pneumoniae inside brain endothelial cells in vivo (Fig. 4A and B
and 5A and B). The groups of pneumococci (blue signal, within
white circles) detected inside the brain vascular endothelium (red
signal) by confocal microscopy were in very close proximity to the
proteasome signal (green), and some bacteria of these groups were
clearly colocalized with proteasome at 1 h and 14 h postinfection
(Fig. 4AB). Furthermore, all the groups of bacteria detected inside
the brain endothelium had the ubiquitin signal (green) on their
surfaces (Fig. 5AB).
DISCUSSION
In this study, we investigated the involvement of the proteasome-
ubiquitin system in the process of killing intracellular S. pneu-
moniae. Apart from regulating protein turnover, the proteasome
system modulates responses to invading and intracellular patho-
genic bacteria, and this modulation has previously been shown for
many other pathogenic bacteria and viruses (8, 9, 12, 28). In our
study, the inhibition of the proteasome-ubiquitin function re-
sulted in a substantial increase in S. pneumoniae survival inside
endothelial cells, indicating that the proteasome-ubiquitin system
is essential for the host cell’s ability to efficiently kill intracellular
S. pneumoniae.
How bacterial pathogens cross the blood-brain barrier is cur-
rently a subject of debate. Diverse studies have described (i) the
destruction of endothelial cell layers in the cases of, for example,
Neisseria meningitidis and the pneumococcal endotoxin pneumo-
lysin (29, 30); (ii) the passage of organisms between brain endo-
thelial cells, causing disruption of cell-cell tight junctions (31);
and (iii) trafficking across the blood-brain barrier by transcytosis,
an intracellular transport route for the transport of molecules and
vesicles through cells from the apical to the basolateral side (4).
The visualization of S. pneumoniae after invasion into the host
cells was shown only using in vitro cell culture models (2–4, 27).
Here we show for the first time to our knowledge that S. pneu-
moniae invades endothelial cells of the blood-brain barrier in vivo.
These findings indicate that S. pneumoniae can invade endothelial
cells without causing major disruptions of the endothelium dur-
ing the translocation across the blood-brain barrier and support
the hypothesis of pneumococcal translocation through either a
pericellular or a transcytosis route. The bacteria were detected
using an antipneumococcal antiserum (see Materials and Meth-
ods) raised against whole heat-killed bacteria. In a recent study, a
preliminary quantification analysis indicated that the number of
pneumococci associated with the brain vascular endothelium de-
tected with anticapsule antibody was not different from the num-
ber detected with the antipneumococcal antiserum (1). If pneu-
mococci had lost their capsule once inside brain endothelial cells,
the number of bacteria detected with the antipneumococcal anti-
serum would have been significantly higher than the number of
bacteria seen with the anticapsule antibody. When interacting
with epithelial cells of the respiratory tract, S. pneumoniae was
shown to lose its capsule (26). Our results suggest that, while in the
brain, S. pneumoniae might maintain its capsule during transloca-
tion over the blood-brain barrier endothelium. Keeping the cap-
sule when translocating over the blood-brain barrier would be an
important advantage for the bacterium in evading the host de-
fenses in the cerebrospinal fluid (CSF). However, this would not
FIG 2 The capsule of S. pneumoniae does not inhibit the proteasome-
mediated killing process. Relative rates of survival of internalized encapsulated
S. pneumoniae during proteasomal inhibition with TET are shown. The con-
trol is set at 100%, and the experimental conditions are related to this percent-
age. Each circle is the relative intracellular survival in an individual experi-
ment, and the horizontal line indicates the average of results from all
experiments (n 9).P value 0.05. Relative intracellular survival is defined as
intracellular survival divided by the amount of the initial invasion.
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impede killing by the proteasome-ubiquitin system, as we show
that this observation was capsule independent (Fig. 2).
The proteasome-ubiquitin system has also been implicated in
the degradation of intracellular Salmonella enterica serovar Typhi-
murium (28, 32). Perrin et al. reported that proteasomes become
associated with the surface of cytosolic Salmonella in macrophages
(32) and that poly-ubiquitinated proteins accumulate on the sur-
faces of these cytosolic bacteria, suggesting that the proteasome-
ubiquitin system might be implicated directly in the clearance of
intracellular Salmonella cells (32). Intracellular pneumococci as-
sociated with both proteasome and ubiquitin signals; however,
with confocal microscopy it is not possible to determine whether
these bacteria are free in the cytosol or in a vesicle. Autophagy was
recently described as a host mechanism of defense against bacte-
ria; in particular, the ubiquitin-mediated recognition of invading
bacteria during the selective autophagy process may be crucial for
host cell survival (33). Although there are no indications that
S. pneumoniae can access the cytosol by escaping the endosome,
our study raises the intriguing possibility that this might occur.
Once in the cytosol, organisms might be (partially) degraded di-
rectly by the proteasome and ubiquitin system, and inhibition of
proteasome may interfere with endocytosis, thus resulting in re-
duced killing of intracellular bacteria.
Alternatively, the role of the proteasome-ubiquitin system in
the degradation of bacteria is indirect. Apart from marking pro-
teins for degradation, the ubiquitination system is involved in
several essential cellular processes, such as cell cycle progression,
DNA repair, and endocytosis (9–11, 32, 34). Given the importance
of these biological processes, it is not surprising that microorgan-
isms have developed mechanisms to interfere with various stages
of the ubiquitin pathway in order to promote their trafficking
inside the host cell. However, as of yet, there are no indications
that S. pneumoniae gains any advantage in its association with the
proteasome-ubiquitin system.
In conclusion, the data described in this paper clearly show that
Streptococcus pneumoniae invades endothelial cells during infec-
tion and that a fully functional proteasome-ubiquitin system in
endothelial cells is crucial for the efficient killing of intracellular
S. pneumoniae. Our study sheds light on S. pneumoniae’s life and
death inside endothelial cells, whose balance may ultimately lead
to bacterial passage across cellular barriers and the development of
invasive disease.
MATERIALS AND METHODS
Bacteremia-derived meningitis model. All experiments involving ani-
mals were performed in strict accordance with Dutch legislation on ani-
mal experiments (35 [modified in 1996 with implementation of the Eu-
ropean guidelines 86/609/EEG], 36), with the prior approval of and in
accordance with guidelines of the Institutional Animal Care and Use
Committee of the University of Groningen (DEC number 6152A). The
bacteremia-derived meningitis model described by Orihuela et al. (37)
was adapted as described before (1). Four groups of 5 female BALB/c
mice, 6 to 8 weeks old (Harlan, Horst, The Netherlands), were anesthe-
tized by inhalation of 2.5% isoflurane before the challenge. Intravenous
tail vein injection with 200 l of 107 CFU of the TIGR4 wild type was
performed. The mice were sacrificed at 1, 3, 8, and 14 h after bacterial
challenge. After sacrifice, to remove unattached bacteria in the blood-
stream, perfusion was performed by injecting sterile phosphate-buffered
saline (PBS) in the right ventricle via the vena cava until the blood was
FIG 3 Confocal microscopy visualization of intracellular S. pneumoniae cells colocalized with proteasome-ubiquitin in vitro. S. pneumoniae (blue) inside
HBMEC and HUVEC (red) colocalizes with proteasome (A) and ubiquitin (B) (both green). The scale of each image is shown by the white bar, which represents
2 m. For each staining, 10 cells were randomly selected for imaging; each image shows 1 cell.
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FIG 4 S. pneumoniae was associated with the proteasome signal inside the brain vascular endothelium of the subarachnoid space. S. pneumoniae (blue, within
white circles) detected inside the brain vascular endothelium (red) by confocal microscopy is associated with the proteasome signal (green) at 1 h (A) and 14 h
(B) postinfection. Bacteria within the white circles are also shown in the enlarged images. For each time point of infection, brains from 3 mice were analyzed, and
from each mouse, 3 brain sections were used for the immunofluorescence detection. These images are representative of observations for each analyzed mouse
brain. The scale of each image is shown by the white bar, which represents 5 m.
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FIG 5 Association between the ubiquitin signal and intracellular S. pneumoniae in mouse brains. Confocal microscopy imaging of the ubiquitin signal (green)
on the surfaces of intracellular bacteria (blue, within white circles) at 1 h (A) and 14 h (B) postinfection. Bacteria within the white circles are also shown in the
enlarged images. For each time point of infection, brains from 3 mice were analyzed, and from each mouse, 3 brain sections were used for the immunofluores-
cence detection. These images are representative of what was observed in each mouse that was analyzed. The scale of each image is shown by the white bar, which
represents 5 m.
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completely removed. Brains, lungs, and spleens were collected and stored
with Shandon Cryomatrix (Thermo Scientific, Runcorn, England) at
80° C.
Bacterial strains and growth conditions. Encapsulated S. pneu-
moniae TIGR4, obtained from C. J. Orihuela (37), was used to challenge
the mice. Bacteria were grown in Todd-Hewitt broth (Oxoid Thermo
Scientific, Basingstoke, United Kingdom), and unencapsulated TIGR4
was grown in M17 medium supplemented with 0.5% glucose (GM17).
Bacteria were harvested at an optical density (OD) at 600 nm of 0.25 to
0.30. One milliliter of encapsulated TIGR4 was centrifuged at 10,000 g
for 3 min and resuspended in sterile PBS (Lonza, Verviers, Belgium) to
generate a challenge dose of 107 CFU/mouse. For the in vitro experiments,
encapsulated S. pneumoniae TIGR4 (38) and its unencapsulated version
(39) were used. Bacteria were grown in M17 medium supplemented with
0.5% glucose (GM17). Cultures were incubated in a 5% CO2 incubator at
37°C. S. pneumoniae aliquots were made by growing bacteria in GM17 to
an OD at 600 nm of ~0.25, mixed to an 11% glycerol concentration, and
then frozen in 1-ml aliquots at80° C
Inhibitors. The concentrations indicated below were selected after
titrating out nonstressful concentrations. Their respective solvents were
used as controls. For ubiquitination and proteasomal inhibition, the fol-
lowing endpoint concentrations were used: tetraethylthiuram disulfide
(TET) (Sigma-Aldrich) at 10M in H2O, MG132 (Calbiochem) at 10M
in dimethyl sulfoxide (DMSO), and UBEI-41 (Biogenova) at 10 M in
DMSO.
Intracellular survival of S. pneumoniae in endothelial cells.HBMEC
(obtained from K. S. Kim) and HUVEC (obtained from the Endothelial
Cell Facility, UMCG) were cultivated as previously described (40, 41).
Prior to infection, confluent HBMEC monolayers in 6- or 12-well plates
were washed repeatedly with RPMI 1640 and incubated for 1 h in cell
culture medium. One-milliliter aliquots of S. pneumoniae (see above)
were centrifuged at 10,000  g for 3 min, and the bacterial pellet was
dissolved in endothelial cell culture medium. Subsequently, ~5 
106 CFU of S. pneumoniae was added to each well and incubated for 2 h;
nonadherent bacteria were removed by repeated washing with RPMI
1640. To assess invasion of the host cell by S. pneumoniae, any remaining
extracellular bacteria were eradicated by a 1-h incubation with cell culture
medium supplemented with gentamicin (50 g/ml) and penicillin G
(2.5 g/ml) and then washed repeatedly with RPMI 1640 and lysed. CFU
were counted by plating serial dilutions on blood agar plates. To assess
intracellular survival, after treatment with gentamicin and penicillin G as
described above, cells were washed repeatedly with RPMI 1640 and new
culture medium containing gentamicin (13.34 g/ml), penicillin G
(0.67 g/ml), and inhibitors of the proteasome-ubiquitin system were
added at phenotypically nonstressful concentrations, which were previ-
ously determined by monitoring the cells microscopically for stress symp-
toms. All inhibitors and bacteria were used at nonstressful concentrations
throughout the assay. Three hours after the addition of inhibitors, the cells
were lysed and plated as described above.
Immunofluorescence detection and image processing. For immu-
nofluorescence detection, endothelial cells were grown on glass coverslips
placed inside each well. In addition to antibiotics, 10 mg/ml of lysozyme
(Sigma-Aldrich) was added to the cell culture medium in order to lyse
extracellular bacteria. After a 2-h incubation with unencapsulated
S. pneumoniae (see “Intracellular survival of S. pneumoniae in endothelial
cells” above), HBMEC and HUVEC were washed with PBS to remove
nonadherent bacteria and fixed with 4% paraformaldehyde (Sigma-
Aldrich). The slides were then washed in PBS three times for 5 min each
time and preincubated using PBS with 0.3% Triton X-100 (Sigma-
Aldrich). For confocal microscopy detection in mice brains, 5-m thin
sections were fixed with acetone for 10 min. After fixation, cells and tissue
sections were incubated with primary antibody for 1 h at room tempera-
ture (RT). After the washing with PBS, incubation with secondary anti-
body for 1 h at RT followed. After the washing with PBS, CitiFluor solu-
tion (Science Services, Munich, Germany) was added to each tissue
section/glass disk. The slides were analyzed with a Leica TC SP8 confocal
microscope, and the z-stacks were merged by means of Imaris (Bitplane
Scientific Software).
Antibodies and lectin. All antibodies and lectin were diluted in sterile
PBS with 5% fetal calf serum (FCS) (Biochrom, Berlin, Germany). To
detect pneumococci, an antipneumococcal antiserum (1) (Eurogentec,
Maastricht, The Netherlands), diluted 1:200, was used in combination
with an Alexa Fluor 350 goat anti-rabbit antibody (Invitrogen Life Tech-
nologies, Carlsbad, CA) at a1:500 dilution. The antipneumococcal antise-
rum was directly labeled with Alexa Fluor 350 (Zenon rabbit IgG labeling
kit; Invitrogen Life Technologies) when used in combination with the
rabbit antiubiquitin antibody. For the detection of endothelial cells, Dy-
Light 594-labeled Lycopersicon esculentum lectin (tomato lectin) (Vector
Laboratories, Burlingame, CA) at a 1:200 dilution was used (13). To detect
proteasome and ubiquitin, respectively, a mouse antiproteasome anti-
body (Abcam, Cambridge, United Kingdom) and a rabbit antiubiquitin
antibody (Acris Antibodies, Herford, Germany) were used, both at a 1:200
dilution, in combination with, respectively, Alexa Fluor 488 goat anti-
mouse antibody (Invitrogen Life Technologies) and Alexa Fluor 488 goat
anti-rabbit antibody (Invitrogen Life Technologies).
Confocal visualization of S. pneumoniae inside brain endothelial
cells in vivo. After the z-stacks were merged, by means of Imaris, xyz series
were generated with the corresponding orthogonal projections in the xz
and zy planes (2). The orthogonal views allowed visualization of the en-
dothelial layer of the subarachnoid space from the x, y, and z axes. In order
to accurately discriminate the location of the bacteria, the whole-cell/
endothelial layer was imaged through the sequential imaging of z-stacks.
Only the bacteria observed inside the endothelial layer in all orthogonal
planes were considered intracellular.
Statistical analysis. The SPSS-16 2-tailed independent-sample t test
was used to determine the significance, presented as a P value, of the
difference between bacterial intracellular survival results of endothelial
cells with and without proteasome-ubiquitin inhibitor.
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